TEVA-DIVALPROEX TABLET (ENTERIC-COATED)

Land: Canada

Taal: Engels

Bron: Health Canada

Werkstoffen:

VALPROIC ACID (DIVALPROEX SODIUM)

Beschikbaar vanaf:

TEVA CANADA LIMITED

ATC-code:

N03AG01

INN (Algemene Internationale Benaming):

VALPROIC ACID

Dosering:

500MG

farmaceutische vorm:

TABLET (ENTERIC-COATED)

Samenstelling:

VALPROIC ACID (DIVALPROEX SODIUM) 500MG

Toedieningsweg:

ORAL

Eenheden in pakket:

100/500

Prescription-type:

Prescription

Therapeutisch gebied:

MISCELLANEOUS ANTICONVULSANTS

Product samenvatting:

Active ingredient group (AIG) number: 0112996003; AHFS:

Autorisatie-status:

CANCELLED POST MARKET

Autorisatie datum:

2020-06-10

Productkenmerken

PRODUCT MONOGRAPH
PR
TEVA-DIVALPROEX
(Divalproex Sodium Enteric-Coated Tablets)
125, 250, 500 mg
USP
Antiepileptic
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario
M1B 2K9
www.tevacanada.com
Submission Control No.: 204247
Date of Revision:
May 1, 2017
_ TEVA-DIVALPROEX_
_ _
_Product Monograph_
_Page 2 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
...................................................... 3
SUMMARY PRODUCT INFORMATION
.....................................................................
3
INDICATIONS AND CLINICAL
USE...........................................................................
3
CONTRAINDICATIONS
................................................................................................
4
WARNINGS AND PRECAUTIONS
..............................................................................
5
ADVERSE REACTIONS
..............................................................................................
21
DRUG INTERACTIONS
...............................................................................................
27
DOSAGE AND ADMINISTRATION
...........................................................................
37
OVERDOSAGE
.............................................................................................................
41
ACTION AND CLINICAL PHARMACOLOGY
......................................................... 41
STORAGE AND STABILITY
......................................................................................
44
DOSAGE FORMS, COMPOSITION AND PACKAGING
.......................................... 44
PART II: SCIENTIFIC INFORMATION
............................................................................
45
PHARMACEUTICAL INFORMATION
......................................................................
45
CLINICAL
TRIALS.......................................................................................................
45
DETAILED PHARMACOLOGY
.................................................................................